Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Buyers

<< Previous

Bullboard Posts

Next >>

Comment by Arbourmarkon Sep 11, 2023 10:14am

321 Views

Post# 35629224

RE:Buyers

Well said Viking, I am on another discussion board and have been saying this for many months now but others on the board feel management can do no wrong. Management needs to figure out why there are no buyers and more importantly why there is 0% institutional ownership. what have they been doing for the past 18 months and what have the 2 strategic advisors brought to the table since being appointed.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market